Who is sponsoring NCT00113295?

NCT00113295 is sponsored by Massachusetts General Hospital.

What condition does NCT00113295 study?

NCT00113295 studies Anxiety Disorder.

What drugs are being tested in NCT00113295?

Interventions: Continued Paroxetine CR, Quetiapine, Placebo.

What is the status of NCT00113295?

NCT00113295 is currently COMPLETED.

Last reviewed 2014-03-20 · How we verify

Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder

NCT00113295 Phase 4 COMPLETED Results posted

The purpose of this study is to examine the safety and efficacy of quetiapine for generalized anxiety disorder patients who remain symptomatic despite treatment with paroxetine CR.

Details

Lead sponsor	Massachusetts General Hospital
Phase	Phase 4
Status	COMPLETED
Enrolment	50
Start date	2004-02
Completion	2007-11

Conditions

Anxiety Disorder

Interventions

Continued Paroxetine CR
Quetiapine
Placebo

Primary outcomes

Hamilton Anxiety Scale (HAM-A) Score at Study Endpoint. — Baseline and Week 18
Symptoms of generalized anxiety disorder as measured by the Hamilton Anxiety Scale (HAM-A) at week 18/study endpoint. Each item is scored on a scale from 0 (not present) to 4 (severe) with a total score range of 0-56. Changes in HAM-A scores are calculated as the difference between the baseline HAM-A scores and scores at week 18/study endpoint. The 14-item Hamilton Anxiety Rating Scale (HAM-A) (Hamilton, 1959) was developed to assess anxiety in a clinical population. It is considered a measure of general anxiety across anxiety disorders, in addition to being a gold standard measure for GAD.

Countries

United States